Management of Type 2 Diabetes Mellitus in the Very Elderly: One Practice’s Experience
Authors' conclusion
Patients with T2DM aged 80 and over respond well to GLP1-RA drugs, drastically reducing the need for agents associated with hypoglycemia. The important question, which will require larger and prospective studies, is whether the lowering of A1c, as shown in this paper, and the use of GLP-1 RA specifically, are associated with improved morbidity and mortality in the very elderly.
Study context
- Population
- Patients aged ≥80 years (mean 88.1, range 80–104) with T2D managed by a single endocrinologist
- Participants
- 85 patients
- Outcome
- Treatment and glycaemic changes in the cohort
- Follow-up
- Mean of 9 months
Methodological detailssingle-centre
- Single-centre
Main finding
As reported in the abstract
mean of 9 months
- Mean A1c in entire cohort, from → to
- 7.6% to 6.6%
- On sulfonylurea and/or insulin, at presentation → later
- 75% → 27%
- Treated with GLP-1 RA
- Nearly one-half
- Required short-acting (bolus) insulin to achieve individualized A1c target
- 0
Observational data: associations, not effects.
Safety
Tolerability of GLP-1 RA
- Beneficial and well-tolerated use of GLP-1 RA
Original publication
Management of Type 2 Diabetes Mellitus in the Very Elderly: One Practice’s Experience. Endocr Pract. Published 24 March 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →